ETCAMAH® (camizestrant)

Company: AstraZeneca

Therapeutic Area: Oncology

Drug Type: Small Molecule

Molecule: Camizestrant (AZD9833)

Clinical Phase: Approved

Pipeline Status: Active

Indication: ER-positive, HER2-negative advanced/metastatic breast cancer; approved for tumors carrying an ESR1 mutation after progression on prior endocrine-based therapy, with additional trials testing broader first-line use.

Mechanism of Action: A next-generation oral selective estrogen receptor degrader (SERD) and pure estrogen receptor antagonist that blocks and degrades the estrogen receptor.

Approved Countries

• UNITED STATES

Clinical Trials

• SERENA-4